Clinical Outcomes and Inflammatory Responses in Viral vs. Bacterial Sepsis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorSichuan Provincial People's Hospital
About this trial
This observational cohort study aims to compare clinical outcomes and inflammatory responses between patients with viral sepsis, specifically COVID-19-associated sepsis, and those with bacterial sepsis. Conducted at Sichuan Provincial People's Hospital, the study will retrospectively analyze data from ICU patients admitted between July 2021 and December 2023. The primary objective is to identify reliable biomarkers and diagnostic methods to improve patient outcomes through personalized diagnostic and therapeutic strategies.
Eligibility criteria
Qualifiers
Patients diagnosed with sepsis according to Sepsis 3.0 criteria.
Patients with confirmed bacterial sepsis based on positive bacterial cultures.
Patients with confirmed viral sepsis, specifically COVID-19, diagnosed via RT-PCR for SARS-CoV-2 for viral group and negative for bacterial group.
Patients aged 18 years and older.
Disqualifiers
Patients with mixed bacterial and viral infections.
Patients with sepsis not meeting the Sepsis 3.0 criteria.
Patients who received immunomodulatory therapies other than standard treatments (e.g., investigational drugs).
Pregnant or breastfeeding women.
Trial design
Treatments tested in this trial
- observation
Treatment groups
300 Participants
are divided into 2 treatment groupsLocations
1Sichuan Provincial People's Hospital610091, ChengduSichuan, China
Sponsors and collaborators
Sichuan Provincial People's Hospital
Lead sponsor
Source ClinicalTrials.gov